Xbrane Gets US Setback For Ranibizumab Filing
BLA For Biosimilar Lucentis Rival Withdrawn As FDA Asks For More Information
Xbrane Biopharma has withdrawn the BLA for its proposed Xlucane ranibizumab biosimilar rival to Lucentis in the US after the FDA said further information was required for it to accept the filing. Development partner Stada said it would “work closely” with Xbrane and US licensee Bausch + Lomb to get the product to market.
You may also be interested in...
Xbrane Refiles Ranibizumab With US FDA
Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.
Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar
Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.
Samsung Bioepis Goes After Lucentis With 40% Cheaper Byooviz Launch In US
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.